Author's response to reviews

Title: Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel group study

Authors:

Lenard Adler (Lenard.Adler@nyumc.org)
Bryan Dirks (bdirks@shire.com)
Patrick Deas (pdeas@shire.com)
Aparna Raychaudhuri (araychaudh@shire.com)
Matthew Dauphin (mdauphin@shire.com)
Keith Saylor (ksaylor@neuroscience-inc.com)
Richard Weisler (RWeisler@aol.com)

Version: 2 Date: 31 January 2013

Author’s response to reviews: see over
1. Consent:
Requesting consent statement:
Please state in the Methods section whether written informed consent for participation in the study was obtained from participants or, where participants are children, a parent or guardian.

**Pg10 pp3 has been revised to address request 1**

2. Please document within the methods section of your manuscript the specific name of the organization that granted ethical approval to your study going ahead.

Ethics: Research involving human subjects (including human material or human data) that is reported in the manuscript must have been performed with the approval of an appropriate ethics committee. Research carried out on humans must be in compliance with the Helsinki Declaration (http://www.wma.net/en/30publications/10policies/b3/index.html). A statement to this effect must appear in the Methods section of the manuscript, including the name of the body which gave approval, with a reference number where appropriate.

**Pg10 pp3 has been revised to address request 2**

3. Study design checklists:
Please adherer to CONSORT guidelines for reporting RCT.

**CONSORT Checklist is included on CK with pg numbers and citations to document adherence to guidelines**